Non-Obstructive Hypertrophic Cardiomyopathy (nHCM) Market Outlook

Thelansis’s “Non-Obstructive Hypertrophic Cardiomyopathy (nHCM) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2025 To 2035” covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Non-Obstructive Hypertrophic Cardiomyopathy treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Non-Obstructive Hypertrophic Cardiomyopathy (nHCM) Overview

Non-obstructive hypertrophic cardiomyopathy (nHCM) is a genetic cardiac disorder caused predominantly by autosomal dominant sarcomere protein mutations in MYH7 and MYBPC3, producing asymmetric left ventricular hypertrophy, myocyte disarray, and myocardial fibrosis without significant left ventricular outflow tract obstruction, defined by resting and provoked peak LVOT gradients below 30 mmHg. Impaired diastolic filling, elevated left ventricular filling pressures, microvascular ischaemia, and arrhythmogenic substrate development drive exertional dyspnoea, angina, fatigue, palpitations, and syncope. Diagnosis integrates clinical assessment, ECG abnormalities, and comprehensive echocardiography, with cardiac MRI quantifying late gadolinium enhancement fibrosis burden as a critical sudden cardiac death risk stratification marker. Beta-blockers and non-dihydropyridine calcium channel blockers improve diastolic function and reduce filling pressures symptomatically. Aficamten, a next-generation cardiac myosin inhibitor, has successfully demonstrated significant improvements in exercise capacity and health status in symptomatic nHCM through the ACACIA-HCM trial, with a favourable and predictable LVEF safety profile, establishing it as the premier disease-targeted therapeutic advance in this setting. ICD implantation addresses significant sudden cardiac death risk following systematic risk stratification. Regular echocardiographic surveillance, Holter monitoring, personalised exercise guidance, genetic counselling, and cascade family screening underpin long-term management; shared decision-making and quality-of-life optimisation are integral to patient-centred care.

Geography coverage:

G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)

Insights driven by robust research, including:

• In-depth interviews with leading KOLs and payers
• Physician surveys
• RWE analysis for claims and EHR datasets
• Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

• Detailed Report (PDF)
• Market Forecast Model (MS Excel-based automated dashboard)
• Epidemiology (MS Excel; interactive tool)
• Executive Insights (PowerPoint presentation)
• Others: regular updates, customizations, consultant support

*As per Thelansis’s policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

• 10-year market forecast (2025–2035)
• Bottom-up patient-based market forecasts validated through the top-down sales methodology
• Covers clinically and commercially-relevant patient populations/ line of therapies
• Annualized drug-level sales and patient share projections
• Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
• Detailed methodology/sources & assumptions
• Graphical and tabular outputs
• Users can customize the model based on requirements

Key business questions answered:

• How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
• How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
• What is the 10-year market outlook for sales and patient share?
• Which events will have the greatest impact on the market’s trajectory?
• What insights do interviewed experts provide on current and emerging treatments?
• Which pipeline products show the most promise, and what is their potential for launch and future positioning?
• What are the key unmet needs and KOL expectations for target profiles?
• What key regulatory and payer requirements must be met to secure drug approval and favorable market access?
• and more…

1. Key Findings and Analyst Commentary

• Key trends: market snapshots, SWOT analysis, commercial benefits and risk, etc..

2. Disease Context

• Disease definition, classification, etiology and pathophysiology, drug targets,etc.

3. Epidemiology

• Key takeaways
• Incidence / Prevalence
• Diagnosed and Drug-Treated populations
• Comorbidities
• Other relevant patient segments

4. Market Size and Forecast

• Key takeaways
• Market drivers and constraints
• Drug-class specific trends
• Country-specific trends

5. Competitive Landscape

• Current therapies
  • Key takeaways
  • Dx and Tx journey/algorithm
  • Key current therapies – profiles and KOL insights
• Emerging therapies
  • Key takeaways
  • Notable late-phase emerging therapies – profiles, launch expectations, KOL insights
  • Notable early-phase pipeline

6. Unmet Need and TPP Analysis

• Top unmet needs and future attainment by emerging therapies
• TPP analysis and KOL expectations

7. Regulatory and Reimbursement Environments (by country and payer insights)

8. Appendix (e.g., bibliography, methodology)